文献速递复苏、休克与脓毒症心脑血管急症

可电击院外心脏骤停患者的胺碘酮剂量

Amiodarone dose in patients with shockable out-of-hospital cardiac arrest.
PubMed 文献 · Resuscitation · 2025-02-11
一句话结论可电击院外心脏骤停且除颤≥5次者,胺碘酮300 mg与450 mg的出院存活无显著差异,300 mg组到急诊科时自主循环恢复概率较高。

本研究基于复苏结局联盟心脏流行病学注册研究(2011-2015年),纳入可电击院外心脏骤停且接受≥5次除颤并接受胺碘酮300 mg或450 mg治疗的患者910例,其中300 mg组426例、450 mg组484例。主要分析采用逆概率加权和多因素logistic回归校正组间差异。300 mg组到急诊科时自主循环恢复的估计概率为30.8%(95%CI 26.6-35.1),高于450 mg组的24.2%(95%CI 20.5-27.9),校正概率差6.6%(0.9-12.3),P=0.0234。出院存活(21.3% vs 18.0%,校正概率差3.3%[-2.3-8.8])和出院时良好神经功能(16.5% vs 12.7%,校正概率差3.8%[-1.2-8.7])组间差异未达统计学显著。作者认为300 mg与450 mg的存活相似,需进一步研究评估是否需要第二次给予胺碘酮。

要点

  • 可电击院外心脏骤停且除颤≥5次者,胺碘酮300 mg组到急诊科时自主循环恢复概率30.8% vs 450 mg组24.2%,校正概率差6.6%(0.9-12.3),P=0.0234。
  • 出院存活300 mg组21.3% vs 450 mg组18.0%,校正概率差3.3%(-2.3-8.8),未达统计学显著。
  • 出院时良好神经功能300 mg组16.5% vs 450 mg组12.7%,校正概率差3.8%(-1.2-8.7),未达统计学显著。
  • 作者认为在除颤≥5次的可电击院外心脏骤停患者中,胺碘酮300 mg与450 mg的存活相似。
  • 作者提出需进一步研究评估可电击院外心脏骤停患者是否需要第二次给予胺碘酮。

适用人群与场景

  • 可电击院外心脏骤停(OHCA)且接受5次或以上除颤尝试、并接受胺碘酮300 mg或450 mg治疗的患者;数据来自复苏结局联盟心脏流行病学注册研究(2011-2015年)。

研究设计与关键结果

  • 研究类型为基于复苏结局联盟心脏流行病学注册研究(2011-2015年)的分析,纳入910例可电击院外心脏骤停且除颤≥5次并接受胺碘酮300 mg或450 mg治疗的患者;300 mg组426例,450 mg组484例;采用逆概率加权和多因素logistic回归校正组间差异。
  • 到急诊科时自主循环恢复:胺碘酮300 mg组30.8%(95%CI 26.6-35.1) vs 450 mg组24.2%(95%CI 20.5-27.9),校正概率差6.6%(0.9-12.3),P=0.0234。
  • 出院存活:胺碘酮300 mg组21.3%(95%CI 17.2-25.4) vs 450 mg组18.0%(95%CI 14.6-21.5),校正概率差3.3%(-2.3-8.8),未达统计学显著。
  • 出院时良好神经功能:胺碘酮300 mg组16.5%(95%CI 12.9-20.2) vs 450 mg组12.7%(95%CI 9.5-16.0),校正概率差3.8%(95%CI -1.2-8.7),未达统计学显著。

证据类型、等级与局限

  • 证据类型:基于复苏结局联盟心脏流行病学注册研究(2011-2015年)的分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在除颤≥5次的可电击院外心脏骤停患者中,胺碘酮300 mg与450 mg的存活相似。
  • 作者提出需进一步研究评估可电击院外心脏骤停患者是否需要第二次给予胺碘酮。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Amiodarone is used in shockable out-of-hospital cardiac arrest (OHCA), but the ideal dose is unknown.

METHODS: This was an analysis from the Resuscitation Outcomes Consortium Cardiac Epidemiologic Registry (2011-2015). Patients with shockable OHCA who received 5 or more defibrillation attempts and treatment with 300 or 450 mg of amiodarone were included. Outcomes were ROSC at ED arrival, survival at hospital discharge, and favorable neurologic function at discharge. Group-differences were adjusted for using inverse probability weighting and a multiple logistic regression model.

RESULTS: The present study included 910 patients; 426 received amiodarone 300 mg and 484 received amiodarone 450 mg. The amiodarone 300 mg group had a higher estimated probability of ROSC at ED arrival as compared with the amiodarone 450 mg group (30.8% [95% CI, 26.6-35.1] vs 24.2% [95% CI, 20.5-27.9], respectively; adjusted probability difference, 6.6% (0.9-12.3), p = 0.0234). The group differences in survival at hospital discharge (21.3% [95% CI, 17.2-25.4] vs 18.0% [95% CI, 14.6-21.5]; adjusted probability difference, 3.3% [-2.3-8.8]) and favorable neurologic outcome at discharge (16.5% [95% CI, 12.9-20.2] vs 12.7% [95% CI, 9.5-16.0]; adjusted probability difference, 3.8% [95% CI, -1.2-8.7]) did not reach statistical significance.

CONCLUSION: In patients with shockable OHCA who received 5 or more defibrillation attempts, a dose of amiodarone 300 mg was associated with a similar survival compared with a total dose of amiodarone 450 mg. Further study is needed to evaluate the need for a second administration of amiodarone in patients with shockable OHCA.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Gelbenegger G, Cheskes S, Jilma B, et al. Amiodarone dose in patients with shockable out-of-hospital cardiac arrest. Resuscitation. 2025. PMID: 39947279. doi:10.1016/j.resuscitation.2025.110534

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。